TARRYTOWN, N.Y., Nov. 5, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the third quarter of 2013 and provided an update on development programs.
The Company reported total revenues of $597 million in the third quarter and $1.494 billion in the first nine months of 2013, compared to $428 million in the third quarter and $964 million in the first nine months of 2012. EYLEA U.S. net product sales grew 49% to $363 million in the third quarter of 2013 from $244 million in the third quarter of 2012.
Help employers find you! Check out all the jobs and post your resume.
